research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
Search
for
Sort by
Research
450-480 / 1000+ results
research A single topical application of calcipotriol (50μg/g) ointment has no acute effect on systemic calcium homeostasis in patients with chronic plaque psoriasis
Putting calcipotriol ointment on the skin once doesn't change calcium levels in the body right away.
research Citrate Anticoagulation in Hemodialysis
Citrate is a safer alternative to heparin for preventing blood clots in hemodialysis.
research Phenobarbital
A woman experienced unusual hair loss and skin reactions after taking phenobarbital, but her hair grew back after treatment.
research Neurosteroids and epileptogenesis in the pilocarpine model: Evidence for a relationship between P450scc induction and length of the latent period
Neurosteroid production in the brain may delay seizure onset.
research Diuretics
Diuretics can cause serious side effects and should be used carefully.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Embryo‐Fetal Developmental Toxicity and Toxicokinetics Studies of YWS1903, a Novel Potassium‐Competitive Acid Blocker, in Pregnant Rats
YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.
research Sodium Valproate Induced Alopecia: A Case Series
Sodium valproate can cause reversible hair loss in some patients.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Glia-derived steroids modulate epileptogenesis in a model of temporal lobe epilepsy
Neurosteroids from glia cells help control seizure development in epilepsy.
research Finasteride
research Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
Ritlecitinib is safe for treating alopecia areata for up to 48 weeks.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.
research Ritlecitinib (Litfulo)
Litfulo is recommended for treating severe alopecia areata in people 12 and older, as it helps hair regrowth.
research This Week in JAMA
Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.
research Role of GABA-active neurosteroids in the efficacy of metyrapone against cocaine addiction
Neurosteroids may help metyrapone reduce cocaine addiction.
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.
research Potassium channel openers: pharmacological and clinical aspects
Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
research Eosinophilic Pleuropericardial Effusion due to Valproic Acid
Valproic acid can cause a rare allergic reaction leading to fluid around the lungs and heart, which is treatable by changing medication.
research Does treatment with clomipramine reduce cat psychogenic alopecia?
Clomipramine alone does not reduce overgrooming in cats with psychogenic alopecia.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Trichotillomania in long COVID successfully treated with escitalopram: A case report
Escitalopram helped a woman with hair-pulling due to long COVID.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Baricitinib works better in adolescents than adults for treating severe alopecia areata.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.